Právní předpis byl sestaven k datu 31.01.2026.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
SDĚLENÍ
Ministerstva xxxxxxxxxxxx xxxx,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx sděluje, xx xxx 1. října 2023 xxxx xxxxxxxxx xxxxxxxxxx UNESCO xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx I - Xxxxxx zakázaných xxxxx x xxxxx xxxxxxx xxx xxx 2024 - Mezinárodní xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve sportu.
S xxxxx xxxxxx Přílohy X vyslovil souhlas Xxxxxxxxx Xxxxx republiky x xxxxxxxxx republiky xxxxxxxx xxxxxxx o xxxxxxx xxxx Xxxxxxx X Xxxxxx republikou.
Nové xxxxx Přílohy I xxxxxxxxx v xxxxxxxx x xxxxxxx x článkem 34 odst. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx xxxxxxxxx x platnost xxx 18. xxxxxx 2024 x xxxxxxxxx Xxxxxxx X pro xxx 2023, platnou xx 1. xxxxx 2023, xxxxx xxxxxxxxx x xxxxxxxx xxx Xxxxxx xxxxxxxxx dne 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.
Xxxxxxxx xxxxx Přílohy X xxx xxx 2024 x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;
Xxxxxxx:
x x. XXXx. Xxxxxx, Xx.X., LL.M., x. x.
xxxxxx ředitel xxxxx xxxxxx x xxxxxxxxxx
&xxxx;
Xxxxxxx č. 1
Xxxxxxx xxxxxxxxxxx xxxxxxx do xxxxxxx xxxxxx
Xxxx
Xxxxxx zakázaných xxxxx x xxxxx xxxxxxx xx povinný Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx antidopingového xxxxxxxx.
Xxxxxx je xxxxxxxxxx xxxxxxxxxxxx xx rozsáhlém xxxxxxxxxxxx procesu xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Seznam xx xxxxxx od 1. xxxxx 2024.
Xxxxxxxxx text Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxx xxxxxxxxx XXXX a xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx. X případě xxxxxxxxxxx xxxxxxxxxxxxx xxxx anglickým x francouzským textem xxxxxxxxx xxxxx v xxxxxxxxxx.
Xxxx xxxx uvedeny xxxxxxx xxxxx používané x xxxxx Seznamu xxxxxxxxxx xxxxx x xxxxx.
Xxxxxxxx Xxx soutěži
Pokud XXXX xxx xxxx xxxxx neschválila xxxx xxxxxx, xx období Xxx soutěži x xxxxxx obdobím xxxxxxxxxxx xxxxx před xxxxxxx (xx 23:59 hodin) x den předcházející Xxxxxxx, xxxxx xx xx Xxxxxxxxx xxxxxxxxx, xx xx xxxxx Xxxxxxx x xxxxxxx xxxxxx Vzorku.
Zakázané xxxxx
Xx xxxxxxx, že xxxx xxxxx nebo metoda xx xxxxxxxx Při xxxxxxx i Xxxx xxxxxx, xxx xx xxxxxxxxxx x Xxxxxx.
Xxxxxxxxxx x Nespecifické
Podle xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 xxxxx všechny Xxxxxxxx xxxxx Xxxxxxxxxxxx látkami, x xxxxxxxx xxxx xxxxxxxxxx v Xxxxxxx xxxxxxxxxx xxxxx a xxxxx xxxxxxx. Žádná Xxxxxxxx xxxxxx nebude Xxxxxxxxxxx xxxxxxx, pokud xxxx v Seznamu xxxxxxxxx označena xxxx Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx k článku „Xxxxxxxxxx xxxxx x Xxxxxxxxxx metody uvedené x xxxxxx 4.2.2 xx xxxxxx xxx xxxxxx způsobem xxxxxxxxxx xx xxxx důležité xxxx xxxx nebezpečné xxx xxxx xxxxxxxxx xxxxx nebo metody. Xxx spíše x xxxxx a metody, xxxxx Xxxxxxxxx pravděpodobně xxxx xxxx xxxxxx x jinému účelu xxx xx zlepšení xxxxxxxxxxx výkonu.“
Návykové xxxxx
Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx xxxx xxxx xxxxxx xxxxxxxx z xxxxxx jejich xxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxx rámec xxxxxx. Xxxx Návykové xxxxx xxxx xxxxxxxxxx xxxx xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).
X0 NESCHVÁLENÉ XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)
Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxxx xxxxxxxxxxxxxx látka, xx xxxxxx xx xxxxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxx Seznamu x xxxxx není x xxxxxxxx xxxx schválena xxxxxx vládním zdravotnickým xxxxxxxxxx orgánem pro xxxxxxx xxxxxxx u xxxx (xxxx. xxxxxx x xxxxxxxxxxxxx nebo xxxxxxxxx vývoji xxxx xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx drogy, xxxxx xxxxxxxxx pouze xxx veterinární xxxxxxx), xx zakázána stále.
Tato xxxxx xxxxxxxx mnoho xxxxxxx xxxxx, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x aktivátory xxxxxxxxx (např. Xxxxxxxxxxx x Xxxxxxxxxx).
X1 ANABOLICKÉ XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Nespecifické látky.
Anabolické xxxxx xxxx xxxxxxxx.
X1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)
Xxx xxxxxxxxx podání, xxxx jiné xxxxxx:
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx) |
&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx; |
&xxxx;•&xxxx; |
xxxxxxxxxx |
|
• |
1-xxxxxxxxxxxxxx (5ɑ-androst-1-en-3,17-dion) |
• |
furazabol (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx) |
|
|
• |
1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on) |
|
|
• |
4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on) |
• |
metenolon |
|
|
• |
5-androstenedion (androst-5-en-3,17-dion) |
• |
metandriol |
|
|
• |
7ɑ-hydroxy-DHEA |
• |
metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
|
|
• |
7-xxxx-XXXX |
&xxxx;• |
xxxxxxxxxxxxxx |
|
|
• |
11ß-xxxxx-19-xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on) |
|
|
• |
19-norandrostenediol (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxx |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (metyltrienolon, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxx (19-xxxxxxxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol) |
• |
norboleton |
|
|
• |
androstenedion (androst-4-en-3,17-dion) |
• |
norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
|
• |
xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxx |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (dehydroepiandrosteron, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on) |
• |
prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- androst-3-en-17ß- xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx) |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxx-xxxxxxxxxxxxxxxxxx (17β-hydroxy-5β-androstan-3-on) |
• |
tetrahydrogestrinon (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx) |
&xxxx;• |
xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX) |
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx biologickými účinky.
S1.2. XXXXXXX XXXXXXXXXX XXXXX
Xxxx xxxx xxxxxx:
Xxxxxxxxxxx, osilodrostat, xxxxxxxxxx, selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. xxxxxxx, enobosarm (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], zeranol a xxxxxxxxxx.
X2 XXXXXXXXX HORMONY, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxxxx látky.
Následující xxxxx x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.
X2.1. XXXXXXXXXXXXX (EPO) X XXXXX XXXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx včetně:
S2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. darbepoetiny (xXXX); xxxxxxxxxxxxx (EPO); sloučeniny xxxxxxxx xx XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA)]; EPO- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, xxxx. XXXX-530, xxxxxxxxxxx.
X2.1.2 Xxxxxxxxx xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (HIF), např. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; molidustat (XXX 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.
X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.
X2.1.4 Inhibitory signalizace xxxxxxxxxxxxxxxx xxxxxxxxx xxxxxxx xxxx (TGF-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.
X2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. xxxxxx XXX; xxxxxxxxxxxxx XXX (XXXX).
X2.2. XXXXXXXXX HORMONY X XXXXXX UVOLŇUJÍCÍ FAKTORY
S2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x mužů, xxxx xxxx xxxxxx:
• xxxxxxxx xxxxxxxxxxxx (XX),
• xxxxxxxxxxxx xxxxxx (LH),
• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) x xxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, xxxxxxxxxx, goserelin, xxxxxxxxx, xxxxxxxxxxx, nafarelin x triptorelin),
• xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.
X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.
X2.2.3 Růstový xxxxxx (XX), jeho xxxxxxx x xxxxxxxxx, mimo xxxx xxxxxx:
• analogy xxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,
• fragmenty růstového xxxxxxx, xxxx. XXX-9604 x hGH 176–191.
S2.2.4 Xxxxxxx xxxxxxxxxx růstový xxxxxx, mimo jiné xxxxxx:
• xxxxxx uvolňující xxxxxxx xxxxxx (GHRH) x xxxx analogy, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx x xxxxxxxxxxx,
• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) a xxxxxx xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (MK-677), xxxxxxxxxx, xxxxxxxxxxx (ghrelin), xxxxxxxxxxx x xxxxxxxxxxx],
• xxxxxxx xxxxxxxxxx XX (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, GHRP-5 a XXXX-6].
X2.3. RŮSTOVÉ XXXXXXX X XXXXXXXXXX RŮSTOVÝCH XXXXXXX
Xxxx xxxx xxxxxx:
• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• hepatocytový růstový xxxxxx (XXX)
• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (IGF-1, xxxxxxxxxx) x xxxx analogy
• xxxxxxxxxx růstové xxxxxxx (XXX)
• xxxxxxx xxxxxx xxxxxxxx x krevních xxxxxxxx (PDGF)
• thymosin-β4 x xxxx xxxxxxxx, xxxx. XX-500
• vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX)
x xxxxx růstové faktory xxxx modulátory xxxxxxxxx xxxxxxx ovlivňující xxxxxxx/xxxxxxxxx xxxxxxxx xx svalech, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx typy svalových xxxxxx.
X3 XXXX-2 XXXXXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx jsou Xxxxxxxxxx látky.
Všichni selektivní x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx všech xxxxxxxxx izomerů jsou xxxxxxxx.
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 mikrogramů xx 24 hodin x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx dávka 54 xxxxxxxxxx xx 24 xxxxx;
• inhalační xxxxxxxxxx: xxxxxxxxx 200 mikrogramů xx 24 xxxxx;
• xxxxxxxxx vilanterol: xxxxxxxxx 25 xxxxxxxxxx xx 24 xxxxx.
XXXXXXXX
Xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxx xxxxxx xxx 1000 ng/ml nebo xxxxxxxxxxx x xxxxxxxx xxxxxx než 40 xx/xx xxxxxxxxxx terapeutickému xxxxxxx xxxxx x xxxx považována za Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx dávky (xxxxxxxxx) xx xx výše xxxxxxx xxxxxxxxx xxxxx.
X4 XXXXXXXXX X METABOLICKÉ XXXXXXXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxxx xxxxx ve xxxxxxx X4.1 x X4.2 xxxx Specifické xxxxx.
Xxxxx xxxxxxxx xx xxxx S4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx hormonové x xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
X4.1. XXXXXXXXXX XXXXXXXX
Xxxx xxxx včetně:
|
• |
2-androstenol (5ɑ-androst-2-en-17-ol) |
• |
androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-3,5-xxxx-7,17-xxxx (arimistan) |
|
|
• |
3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
4-xxxxxxxxx-3,6,17 trion (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. ANTIESTROGENNÍ XXXXX [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]
Xxxx jiné včetně:
|
• |
arformoterol |
• |
indakaterol |
• |
reproterol |
• |
tretoquinol (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. LÁTKY XXXXXXXXXXX XXXXXXXX XXXXXXXXX XXXXXXXX XXX
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx A |
• |
inhibitory xxxxxxxxxx, např.: |
|
|
• |
konkurenty xxxxxxxxx xxxxxxxx XXX, xxxx.: |
- xxxxx snižující xxxx xxxxxx xxxxxxx xxxxxxxxxx |
||
|
- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031) |
- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx) |
|||
|
• |
xxxxxxxxxx xxxxx receptoru xxxxxxxx XXX (xxxx. xxxxxxxxxx) |
- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx prekurzory (např. xxxxxxxxxxx, domagro xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx) |
X4.4. METABOLICKÉ XXXXXXXXXX
X4.4.1 aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, agonisté xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx receptoru xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) kyselina xxxxxx (XX1516, XX501516) x xxxxxxxx Xxx-xxxɑ , xxxx. SR9009, XX9011
X4.4.2 insuliny x xxxxxxxx xxxxxxxx
X4.4.3 xxxxxxxxx
X4.4.4 xxxxxxxxxxxx
X5 DIURETIKA A XXXXXXXXX XXXXX
XXXXXXXX STÁLE (XXX XXXXXXX I XXXX SOUTĚŽ)
Všechny zakázané xxxxx v xxxx xxxxx jsou Specifické xxxxx.
Xxxxxxx xxxxxxxxx a xxxxxxxxx xxxxx, xxxxxx xxxxx xxxxxxxxx izomerů, xxxx. d- x x-, xxxx xxxxxxxx.
Xxxx xxxx včetně:
• Xxxxxxxxx, xxxx xxxx.:
xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; kanrenon; chlortalidon; xxxxxxxx xxxxxxxxxx; furosemid; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx, xxxx. bendroflumethiazid, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;
• Xxxxxxx, xxxx. xxxxxxxxxx, mozavaptan, xxxxxxxxx;
• Plazmatické xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, xxxx.:
xxxxxxx, xxxxxxx, xxxxxxxxxxx škrob, xxxxxxxx;
• Xxxxxxxxxxx;
• Xxxxxxxxxx;
x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
XXXXXXX
• drospirenon; pamabrom; x xxxxxxx oftalmologické xxxxxxxx inhibitorů xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxxx);
• xxxxxxx xxxxxx xxxxxxxxxxx x xxxxx xxxxxxxxx.
XXXXXXXX
Xxxxx xxxxxxxxxxx množství látky xx xxxxxxxxxx xxxxxxxx xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx x pseudoefedrinu xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Xxx Soutěži ve xxxxxxx s xxxxxxxxxx xxxx jinou xxxxxxxxx xxxxxx (kromě xxxxxxxxx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx felypresinu v xxxxxxxx anestezii), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) xx tuto xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx látku.
ZAKÁZANÉ XXXXXX
XXXXXXXX XXXXX (XXX SOUTĚŽI X MIMO SOUTĚŽ)
Všechny xxxxxxxx metody x xxxx xxxxx xxxx Xxxxxxxxxxxx x výjimkou xxxxx x M2.2, xxx jsou Xxxxxxxxxx xxxxxx.
X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X1.1. Xxxxxx xxxx xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxx z xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx do oběhového xxxxxxx s xxxxxxxx xxxxxxxx xxxxxx nebo xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxxxx odběrovém xxxxxx.
X1.2. Umělé zvyšování xxxxxx, xxxxxxx xxxx xxxxxxx kyslíku.
Mimo xxxx xxxxxx:
Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx a xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xx xxxx hemoglobinu a xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x výjimkou xxxxxxxxxxx xxxxxxx xxxxxxxx.
X1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx manipulace x xxxx nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx nebo chemickými xxxxxxx.
X2. CHEMICKÁ A XXXXXXXXX MANIPULACE
Zakázané xx xxxxxxxxxxx:
X2.1. Podvádění nebo Xxxxx x xxxxxx xx účelem xxxxxxx xxxxxxxxx a xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Xxxxxx.
X2.2. Xxxxxxxxxx xxxxxx a/nebo xxxxxxx xxxx než xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx ošetření, chirurgických xxxxxxx xxxx klinických xxxxxxxxxxxxxx xxxxxxxxx.
X3. GENOVÝ X XXXXXXX XXXXXX
X xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:
X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx nebo xxxxxx xxxxxxx, xxxxx xxxxx změnit xxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx jiné xxxxxxxx xxxxxxxxxxx xxxxx xxxx, xxxxxxxxx xxxx x technologie xxxxxxx xxxx.
X3.2. Použití normálních xxxx xxxxxxxxx modifikovaných xxxxx.
X6 XXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx zakázané xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx x xxxxxxxx xxxxx xxxxxxxxx v X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx v xxxx xxxxx: kokain x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)
Všechna xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- a x-, xxxx xxxxxxxx.
Xxxxxxxxxxx xxxxxxxx:
X6.X: XXXXXXXXXXXX XXXXXXXXXXX
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx [4-fenylpiracetam (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx x xxxxx xxxxxx, xx Xxxxxxxxxxx látkou.
S6.B: XXXXXXXXXX XXXXXXXXXXX
Xxxx jiné včetně:
|
• |
2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, BMPEA) |
• |
famprofazon |
• |
oktopamin |
||
|
• |
3-metylhexan-2-amin (1,2-dimetylpentylamin) |
• |
fenbutrazát |
• |
oxilofrin (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-dimetylamylamin, 1,3 XXXX, xxxxxxxxxxxxxx) |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
4-xxxxxxxxxxxx-2-xxxx (1,3-dimethylbutylamin) |
• |
hydrafinil (xxxxxxxxx) |
• |
xxxxxxxxxxx x xxxx xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (parahydroxyamfetamin) |
• |
fenmetrazin |
||
|
• |
benzfetamin |
• |
isomethepten |
• |
fenprometamin |
||
|
• |
katin1) |
• |
levmetamfetamin |
• |
propylhexedrin |
||
|
• |
katinon a xxxx analogy, xxxx. xxxxxxxx, metedron x ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxx3) |
• |
xxxxxxxxxxxx3) |
• |
xxxxxxxxxx |
||
|
• |
xxxxxxxxx (xxxxxxxxx)4) |
• |
xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx] |
• |
xxxxxxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx) |
||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxx (1,5-xxxxxxxxxxxxxxxx) |
x další látky x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx
XXXXXXX
• xxxxxxxx;
• xxxxxxxx xxxxxxxxxxx x xxxxxxx xxxxxx xxxxxxx, xxxxxxx, očního nebo xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, nafazolin, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x xxxxxxxxxxx zařazená xx Xxxxxxxxxxxxxx xxxxxxxx 20245).
X7 XXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx zakázané látky x této xxxxx xxxx Specifické látky.
Návykové xxxxx v xxxx xxxxx: xxxxxxxxx (xxxxxx)
Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. d- x x, xxxx xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx x xxxx xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (xxxxxx) |
• |
xxxxxxx |
• |
xxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxxx |
X8 XXXXXXXXXXX
XXXXXXXX XXX SOUTĚŽI
Všechny xxxxxxxx xxxxx v xxxx xxxxx xxxx Specifické xxxxx. Návykové xxxxx x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)
Xxxxxxx přírodní x xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx, např.
• x konopí (xxxxx, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx
• přírodní x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (THC)
• xxxxxxxxxx kanabinoidy xxxxxxxxxxxx xxxxxx XXX
XXXXXXX
• xxxxxxxxxx
X9 XXXXXXXXXXXXXXX
XXXXXXXX XXX SOUTĚŽI
Všechny xxxxxxxx xxxxx x xxxx třídě jsou Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, perorální [xxxxxx xxxxxxxxxx (např. xxxxxxx, xxxxxxxxxx, sublingvální)] nebo xxxxxxxx cestou.
Mimo xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx acetonid |
||
|
• |
kortizon |
• |
hydrokortizon |
||||
|
• |
deflazakort |
• |
metylprednisolon |
POZNÁMKA
• Xxxx xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx a xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, ušního x xxxxxxxxxxxx) xxxxxx zakázány, xxxxx xx používají x xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxx.
X1 XXXX-XXXXXXXXX
XXXXXXXX X URČITÝCH XXXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx sportech Při Xxxxxxx a xxx xx xx xxxxxxxx xxxxxxxx (*) x Xxxx soutěž.
• xxxxxxxxxxx (XX)*
• lyžování/snowboarding (XXX) – skoky na xxxxxx, xxxxxxxxxxx xxxxx / U-rampa a xxxxxxxxx X-xxxxx / xxx xxx
• xxxxxxxxxxxx xxxxx (FIA)
• podvodní xxxxxx (XXXX)* v xxxxxxxxxxxx volného xxxxxxxx, xxxx xxxxxxxx x xxxxxxx na xxxx
• xxxxxxxx (xxxxxxx disciplíny) (XXXX)
• xxxxx (XXX)
• xxxx (IGF)
• minigolf (XXX)
• střelba (ISSF, XXX)*
* xxxxxxxx také Xxxx soutěž
Mimo jiné xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx x. 2
Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;
1) xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: xx zakázaný xxxxx při xxxxxxxxxxx x xxxx xxxxx xxx 5 xxxxxxxxxx x 1 ml.
2) xxxxxxxxxxxxx: xxxxxxxx xxxxx xxx xxxxxxxxxxx x xxxx vyšší xxx 150 mikrogramů v 1 xx.
3) xxxxxxx x xxxxxxxxxxxx: xxxxxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 10 mikrogramů x 1 ml.
4) xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, xxxx. xxxxx, xxxx, xxxx xxxxxxxx podávání x xxxxxxxxx xxxxxxxxxx.
5) xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 19/2025 Sb. xxxxx xxxxxxxxx xxxx 28.1.2024.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, pokud se xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx